Small caps stole the show on Tuesday as the Russell 2000 jumped about 1.7% while the Nasdaq went nowhere, and the after-hours session added a fresh batch of movers. A diagnostics company surged on an asset sale, an FDA decision date for a small biotech is now 10 days away, and a lab-supplies stock fell more than 20% after the bell. With Tesla and Meta reporting after Wednesday’s close, here are 10 stocks under $15 to watch tomorrow, built around smaller and lesser-known names. None of them appeared in our recent watchlists, and every price below is labeled with what we could and could not verify.
Stocks Under $15 to Watch Tomorrow: Tuesday’s Market Snapshot
| Metric | Tuesday Close / Reading |
|---|---|
| Dow Jones Industrial Average | 52,495.88 (+1.02%) |
| S&P 500 | 7,712.57 (+0.28%) |
| Nasdaq Composite | 26,424.82 (-0.02%) |
| Russell 2000 | ~2,773 (+1.65%; sources show 2,773.42–2,776.83) |
| Strongest S&P Sector | Health care (+2.33%) |
| Oil | Retreated from near five-month highs |
The Russell 2000 led the major indexes in a broad rotation while the Nasdaq slipped slightly, and health care hit all-time highs. The Dow gained more than 500 points on a 3M beat and a drop in oil, and after the bell SpaceX, Capital One and Super Micro rose while United Airlines fell. Tesla and Meta report after Wednesday’s close, which keeps the Nasdaq in focus.
Data note: Prices are Tuesday, October 20 figures where verified. Several are midday or after-hours quotes and say so, and “est.” means derived from a verified percentage move. Where a field could not be verified, the table says “not confirmed” rather than guessing. RSI and MACD are omitted because feeds were stale. Support and resistance levels are analytical zones built from verified prices, 52-week extremes and analyst targets, not guaranteed targets. These are speculative stocks, several with micro-cap market values.
1. Myriad Genetics (MYGN) | $5.62 Midday (+33.5%) | Selling Prenatal Health to Labcorp
A Struggling Diagnostics Stock Jumps a Third on an Asset Sale
Myriad shot up 33% after announcing it will sell its Prenatal Health testing business to Labcorp.
| Metric | Value |
|---|---|
| Price | $5.62 at midday (+33.5%); prior close ~$4.21 (est.) |
| 52-Week Range | $2.74 – $8.59 |
| Market Cap | ~$540M at $5.62 (est.; 95.65M shares) |
| P/E / Dividend | Negative (EPS -$1.20) / None |
| Volume vs. Average | Not confirmed; average ~2.1M–2.4M shares |
| Analyst View | Hold; average target ~$3.77 (9 analysts), below the new price |
| Short Interest | 8.5M shares (8.9% of float, Aug. 19) |
| Q2 Revenue | $190.7M (-11% YoY) |
| Support 1 / 2 / 3 | $4.21 / $3.20 / $2.74 |
| Resistance 1 / 2 / 3 | $5.62 / $6.00 / $8.59 |
Catalyst & Latest News: Hasbro, Equifax and Northrop also rose Tuesday, but Myriad was one of the standout movers. Terms of the sale were not confirmed in the sources we reviewed.
Technicals: The stock sits well above every published analyst target. BofA has $3.20 with an Underperform rating, and Stephens has $3.
Fundamentals: Q2 revenue fell 11% on lower prenatal volumes and payer friction, so selling the weakest unit changes the story. Equibles lists the next earnings call around October 26, unconfirmed.
Bull Case: A cleaner business, fresh cash and a heavily shorted stock. Bear Case: The stock now trades about 49% above the average target, and prenatal was a large revenue line.
What to Watch:
- Sale price and use of proceeds
- Analyst target resets
- A hold of $4.21, the gap level
Forecast: Holding $4.21 keeps the breakout alive toward $6. A fade through it would signal the sale was already priced in.
Why This Matters: MYGN shows how a divestiture can reset a battered turnaround overnight.
2. Hertz (HTZ) | $2.10 Midday (+13.8%) | Oro Mobility Lands $80 Million
The Rental-Car Stock Bounces on a Fleet-Platform Investment
Hertz said Oro Mobility secured an $80 million strategic equity investment from a consortium of investors, and the stock rose 13.8% to $2.10.
| Metric | Value |
|---|---|
| Price | $2.10 at midday (+13.8%); prior close ~$1.85 (est.) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$0.65B (est.; ~316M shares) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Hold; older targets ~$5–$5.50 (Northcoast Neutral, $5) |
| Oro Deal | ~$80.89M investor purchase closed Oct. 16 |
| Support 1 / 2 / 3 | $1.85 / $1.75 / $1.50 |
| Resistance 1 / 2 / 3 | $2.10 / $2.50 / $3.00 |
Catalyst & Latest News: An 8-K describes an investor purchase of Oro equity units for about $80.9 million, closed October 16, and a separate purchase of second-lien notes at a 60% discount to par for about $20.9 million. Hertz also transferred assets and roughly $60 million of cash to Oro.
Technicals: The stock was near $6 in the spring, so $2.10 is far below older levels, and the targets below are stale.
Fundamentals: Hertz launched Oro Mobility in April with Uber as its first partner, and Q1’s adjusted EPS was -$0.72 with a $837 million liquidity position at quarter end.
Bull Case: Outside capital for Oro and a discounted debt buyback. Bear Case: Heavy losses, a collapsed share price and analyst targets that have not caught up.
What to Watch:
- A hold of $1.85
- Analyst updates reflecting the lower price
- Oro deployment news
Forecast: A close above $2.10 targets $2.50. A slip under $1.85 would erase the move.
Why This Matters: HTZ is a levered turnaround where a financing headline can move the stock double digits.
3. Inovio Pharmaceuticals (INO) | Close $1.01 | After-Hours +12.9% to $1.14 | FDA Date Is October 30
Ten Days to a PDUFA Decision and a $104 Million Market Cap
The FDA set a target action date of October 30, 2026 for Inovio’s INO-3107, a treatment for recurrent respiratory papillomatosis, and shares rose 12.9% after hours.
| Metric | Value |
|---|---|
| Last Close | $1.01 (Oct 20); after-hours $1.14 (+12.9%) |
| 52-Week Range | $0.56 – $2.98 |
| Market Cap | ~$104M |
| P/E / Dividend | Negative (EPS about -$1.03) / None |
| Volume vs. Average | Not confirmed; average ~3.7M shares |
| Analyst View | Buy (3 analysts); average target ~$3.17 |
| Key Date | PDUFA Oct 30, 2026; earnings est. Nov 10 |
| Cash | Runway into Q1 2027 after a $16M raise; $20M offering also priced |
| Support 1 / 2 / 3 | $1.01 / $0.90 / $0.56 |
| Resistance 1 / 2 / 3 | $1.14 / $1.29 / $2.00 |
Catalyst & Latest News: Regulatory review is progressing, with FDA inspections complete. TNN’s Capricor forecast shows how these decision clocks can swing small-cap biotechs in either direction.
Technicals: Yahoo shows the stock in the $1.25–$1.30 area earlier in the period, so $1.01 sits well below, and $1.29 is the nearest overhead level.
Fundamentals: Wainwright lowered its target to $2.50 from $3 with a Neutral rating, and the company has raised equity repeatedly.
Bull Case: A pending FDA decision on a drug for a rare disease, targets triple the price. Bear Case: Binary FDA risk, a thin cash runway and prior dilution.
What to Watch:
- Any pre-PDUFA FDA communication
- A hold of $1.01
- Financing news before the decision
Forecast: Run-up behavior into a PDUFA is common, so a hold above $1.01 keeps $1.29 in reach. A negative FDA headline would likely test $0.90.
Why This Matters: INO is a pure event trade with a date on the calendar.
4. Energy Vault (NRGV) | Close ~$2.75 (est.) | After-Hours +7% to $2.94
The Energy-Storage Developer Pops After the Bell With No Verified Catalyst
Energy Vault rose 7% to $2.94 in Tuesday’s after-market session with a market cap near $504 million.
| Metric | Value |
|---|---|
| Last Close | ~$2.75 (est.); after-hours $2.94 (+7.0%) |
| 52-Week Range | $1.02 – $6.645 |
| Market Cap | ~$504M (after-hours) |
| P/E / Dividend | Negative (EPS about -$0.71) / None |
| Volume vs. Average | Not confirmed; average ~5.5M shares |
| Analyst View | Citigroup Buy; 1-year target ~$5.58 |
| Short Float | ~20.8% (older data) |
| Support 1 / 2 / 3 | $2.75 / $2.50 / $2.00 |
| Resistance 1 / 2 / 3 | $2.94 / $3.50 / $3.74 |
Catalyst & Latest News: We could not verify a company announcement behind the after-hours move. Citigroup reiterated a Buy rating in August.
Technicals: The stock traded near $3.48–$3.74 in August, so those levels are overhead resistance after the pullback.
Fundamentals: The company builds utility-scale storage in the U.S., Switzerland, the U.K. and Australia, and began construction on its Texas Sosa Energy Center in January.
Bull Case: Grid-storage demand tied to AI power needs, and a heavily shorted stock. Bear Case: Losses, convertible financing and a 20% short float that cuts both ways. TNN’s September trending-stocks coverage tracked the same power-and-AI theme.
What to Watch:
- A hold of $2.75
- Any press release explaining the move
- Short-covering volume
Forecast: A close above $2.94 points to $3.50. Without news, expect the after-hours pop to fade toward $2.50.
Why This Matters: NRGV is a high-short-interest name that can move on very little.
5. Alpha Teknova (TKNO) | Close $7.39 | After-Hours About -23% to ~$5.63
A Lab-Supplies Stock Near Its Yearly High Gives Back a Quarter of Its Value
Teknova fell 22.2% to $5.75 in after-market trading, and another feed showed $5.63, down 23.8% from a $7.39 close.
| Metric | Value |
|---|---|
| Last Close | $7.39 (Oct 20); after-hours ~$5.63–$5.75 (about -22% to -24%) |
| 52-Week Range | $1.91 – $7.84 |
| Market Cap | ~$397M at the close |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed; average ~216K shares |
| Short Interest | 2.8% of float, ~17 days to cover (Aug. 20) |
| Analyst View | Buy ratings from Craig-Hallum and TD Cowen (2025); target ~$8.60 (est.) |
| Support 1 / 2 / 3 | $5.63 / $5.24 / $3.55 |
| Resistance 1 / 2 / 3 | $7.39 / $7.84 / $8.60 |
Catalyst & Latest News: An Investing.com summary says the stock slid despite beats as investors weigh timing risks for 2027 growth drivers, and we could not confirm the underlying press release.
Technicals: The close was within 6% of the 52-week high of $7.84, so the after-hours drop gives back months of gains.
Fundamentals: Teknova reaffirmed 2026 revenue guidance earlier in the year. The stock had climbed from $2.42 in January.
Bull Case: A strong year, reaffirmed guidance and a premium biotech-tools niche. Bear Case: A premium valuation and a gap-down on thin volume.
What to Watch:
- Opening price versus $5.63
- The company’s release
- Volume against the ~216K average
Forecast: A hold above $5.63 would limit the damage. A break under $5.24 puts the July level near $3.55 into view.
Why This Matters: TKNO shows how a stock near its high can drop 20%+ in one session.
6. Braiin (BRAI) | Close ~$4.29 (est.) | After-Hours +10.6% to $4.75
An AI-Platform Micro-Giant Worth $900 Million With Five Employees
Braiin rose 10.63% to $4.75 in Tuesday’s after-market session, with a market cap of about $921 million.
| Metric | Value |
|---|---|
| Last Close | ~$4.29 (est.); after-hours $4.75 (+10.6%) |
| Recent Quotes | $4.80 (Oct 9); $5.63 (Aug 20); $6.18 (Jul 24) |
| 52-Week Range | Low ~$4.19; the high differs by source after a 3-for-1 split |
| Market Cap | ~$921M (after-hours) |
| P/E / Dividend | Not meaningful / None |
| Volume vs. Average | Not confirmed; average ~114K–450K shares |
| Analyst View | Maxim Buy, $10 target (one analyst) |
| Support 1 / 2 / 3 | $4.19 / $4.00 / $3.50 |
| Resistance 1 / 2 / 3 | $4.75 / $4.80 / $5.63 |
Catalyst & Latest News: The stock jumped 74% in one session earlier this year on a reported £25 billion Switchcraft contract, and it announced a 3-for-1 stock split and a Home.cc partnership.
Technicals: Google Finance lists a 52-week low near $4.19, and the stock is probing that level.
Fundamentals: Braiin is an Australian company with about five employees, and Benzinga shows no upcoming earnings date.
Bull Case: A big announced contract pipeline and one Buy rating. Bear Case: A near-$1 billion valuation with no meaningful revenue and a stock that has fallen from far higher levels.
What to Watch:
- A hold of $4.19
- Any contract update
- Liquidity on thin volume
Forecast: Reclaiming $4.80 would ease pressure. A break under $4.19 would mean fresh lows.
Why This Matters: BRAI is a valuation-versus-fundamentals test for AI-labeled micro-caps.
7. Acrivon Therapeutics (ACRV) | Close $1.80 | After-Hours +6.9% to $1.92
An Oncology Biotech With Seven Analysts and a Q4 Interim Readout
Acrivon rose 6.87% to $1.92 after hours from a $1.80 close, with a market cap near $77 million.
| Metric | Value |
|---|---|
| Last Close | $1.80 (Oct 20); after-hours $1.92 (+6.9%) |
| 52-Week Range | $1.27 – $3.56 |
| Market Cap | ~$77M |
| P/E / Dividend | Negative (EPS about -$2.12) / None |
| Volume vs. Average | Not confirmed; three-month average ~390K shares |
| Analyst View | Strong Buy (7 analysts); average target $11.50; Oppenheimer $8 |
| Key Catalyst | ACR-368 Phase 2b interim analysis, Q4 2026 |
| Support 1 / 2 / 3 | $1.80 / $1.76 / $1.27 |
| Resistance 1 / 2 / 3 | $1.92 / $2.05 / $3.56 |
Catalyst & Latest News: ACR-368 showed a 52% confirmed response rate in serous endometrial cancer, and an interim analysis is planned. Oppenheimer assumed coverage at Outperform with an $8 target.
Technicals: The October monthly price is near $1.76 and September was $2.05, so those are the nearest levels.
Fundamentals: The company also develops ACR-2316, which advanced into randomized dose expansion, and has about 75 employees.
Bull Case: A strong early response rate and a pivotal-style interim analysis due this quarter. Bear Case: Analysts have flagged competition from Eisai’s E7386, and efficacy in biomarker-negative patients is lower.
What to Watch:
- Any interim-data date announcement
- A hold of $1.76
- Cash runway commentary
Forecast: A close above $1.92 targets $2.05. Without news, the stock likely stays range-bound until the interim readout.
Why This Matters: ACRV is an oncology catalyst-in-waiting trading at a fraction of analyst targets.
8. Conexeu Sciences (CNXU) | Close $2.99 | After-Hours +9.7% to $3.28
A Four-Employee Regenerative-Materials Company Trades Far Below Its Old Low
Conexeu rose 9.7% to $3.28 in Tuesday’s after-hours session from a $2.99 close, with a market cap near $84 million.
| Metric | Value |
|---|---|
| Last Close | $2.99 (Oct 20); after-hours $3.28 (+9.7%) |
| Recent Quotes | $3.30 (Oct 9); $4.97 (Sept 4); $9.07 (Aug 6) |
| 52-Week Range | $18.79 high; prior $4.00 low now broken |
| Market Cap | ~$84M (after-hours) |
| P/E / Dividend | Negative (EPS about -$0.34) / None |
| Volume vs. Average | Not confirmed; average ~121K shares |
| Analyst View | HC Wainwright Buy, $20 target |
| Fiscal Year End | October 31 |
| Support 1 / 2 / 3 | $2.99 / $2.50 / $2.00 |
| Resistance 1 / 2 / 3 | $3.28 / $3.30 / $4.00 |
Catalyst & Latest News: HC Wainwright initiated at Buy with a $20 target in June, and we could not verify a fresh catalyst for Tuesday’s move.
Technicals: The stock traded at $9.07 in early August and $4.97 in early September, so it has roughly lost two-thirds of its value in under three months.
Fundamentals: Conexeu develops collagen-based regenerative scaffold products for aesthetics and tissue repair, per Yahoo, with just four employees per Robinhood.
Bull Case: A heavily sold stock with a $20 target. Bear Case: A steady slide, a tiny team and no verified catalyst.
What to Watch:
- A hold of $2.99
- Any new filing or trial update
- A rebound above $3.30
Forecast: A close above $3.30 would be the first sign of a base. A break below $2.99 opens $2.50.
Why This Matters: CNXU is a falling-knife setup with an analyst target 6x the price.
9. Aqua Metals (AQMS) | Close $1.42 | After-Hours +16.2% to $1.65
A $5 Million Industrials Micro-Cap Pops 16% After the Bell
Aqua Metals rose 5.6% to $1.50 in one after-hours listing and 16.2% to $1.65 in another, with a market cap of about $5 million.
| Metric | Value |
|---|---|
| Last Close | $1.42 (Oct 20); after-hours $1.50–$1.65 (+5.6% to +16.2%) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$5.1M (after-hours) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $1.42 / $1.25 / $1.00 |
| Resistance 1 / 2 / 3 | $1.65 / $2.00 / $2.50 |
Catalyst & Latest News: We could not verify a company announcement. The two after-hours feeds disagree on the size of the move, which is common in thin trading.
Technicals: The levels above are round-number zones anchored on the verified close and after-hours range, because no 52-week data was confirmed.
Fundamentals: Benzinga lists Aqua Metals in its industrials movers, and a market value of about $5 million means even small orders can move the stock.
Bull Case: An oversold micro-cap with a sharp after-hours bid. Bear Case: A market value near $5 million, no verified news and wide quote disagreement.
What to Watch:
- Whether the after-hours bid holds at the open
- Any press release
- Dilution risk
Forecast: A hold above $1.42 keeps a bounce alive. A fade under $1.25 would erase it. TNN’s penny-stock coverage explains why liquidity is the main risk here.
Why This Matters: AQMS is a reminder that after-hours spikes in micro-caps often do not survive the open.
10. Edesa Biotech (EDSA) | Close ~$2.82 (est.) | After-Hours +11.7% to $3.15
A $27 Million Biotech Moves on Thin After-Hours Volume
| Metric | Value |
|---|---|
| Last Close | ~$2.82 (est.); after-hours $3.15 (+11.7%) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$26.8M (after-hours) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $2.82 / $2.50 / $2.00 |
| Resistance 1 / 2 / 3 | $3.15 / $3.50 / $4.00 |
Catalyst & Latest News: We could not verify a company announcement behind the move, so treat it as a trading-flow story until the company says otherwise.
Technicals: The levels are round-number zones anchored on the derived close and the after-hours price.
Fundamentals: Benzinga lists Edesa in its health-care movers. We did not verify pipeline, trial or cash figures for this article.
Bull Case: A low market cap and a sharp after-hours bid. Bear Case: Tiny float, no verified news and a high chance of a fade.
What to Watch:
- The open versus $3.15
- Any 8-K or press release
- Offering risk
Forecast: A hold above $2.82 keeps the bounce intact. A fade under $2.50 would suggest the move was noise.
Why This Matters: EDSA belongs on the list as a high-risk watch name, not a conviction idea.
Stocks Under $15 to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Healthcare is the busiest corner, with Myriad’s asset sale, Inovio’s FDA countdown, Acrivon’s interim readout and a sharp after-hours drop in Teknova all on the list. Health care also led the S&P 500 and hit all-time highs, which helps risk appetite for small biotechs. Small-cap breadth was strong Tuesday, but the most extreme after-hours moves came in names with market values under $100 million, where one headline or one order can move the price. Our forecast for Wednesday: expect profit-taking in names that spiked, and watch Tesla and Meta after the close for a read on the Nasdaq.
At a Glance: Stocks Under $15 to Watch Tomorrow (Oct 21, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | MYGN | $5.62 (midday) | +33.5% | Prenatal sale to Labcorp | $4.21 / $6.00 |
| 2 | HTZ | $2.10 (midday) | +13.8% | Oro $80M investment | $1.85 / $2.50 |
| 3 | INO | $1.01 (AH $1.14) | +12.9% AH | PDUFA Oct. 30 | $1.01 / $1.29 |
| 4 | NRGV | ~$2.75 (AH $2.94) | +7.0% AH | No verified news | $2.75 / $3.50 |
| 5 | TKNO | $7.39 (AH ~$5.63) | ~-23% AH | After-hours plunge | $5.63 / $7.39 |
| 6 | BRAI | ~$4.29 (AH $4.75) | +10.6% AH | Near 52-week low | $4.19 / $4.80 |
| 7 | ACRV | $1.80 (AH $1.92) | +6.9% AH | Q4 interim data | $1.76 / $2.05 |
| 8 | CNXU | $2.99 (AH $3.28) | +9.7% AH | Rebound from lows | $2.99 / $3.30 |
| 9 | AQMS | $1.42 (AH $1.65) | +16.2% AH | No verified news | $1.42 / $1.65 |
| 10 | EDSA | ~$2.82 (AH $3.15) | +11.7% AH | No verified news | $2.82 / $3.15 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, clinical-stage biotech and other high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change, particularly after-hours quotes. Several prices are midday or after-hours figures or are estimated from verified percentage moves, and fields marked “not confirmed” were not verified. Support and resistance levels are analytical reference zones, not guaranteed price targets. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
